|By PR Newswire||
|December 29, 2013 01:00 AM EST||
-- Full Spectrum Endoscopy Soon Available in the Country of Its Invention
CAESAREA, Israel, Dec. 29, 2013 /PRNewswire/ -- EndoChoice® today announced the company has received clearance to market their innovative Fuse™ Full Spectrum Endoscopy™ in Israel. The clearance by the Ministry of Health means Fuse will be the first endoscopy system available with expanding viewing capabilities to reach patients in Israel. Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients.
The Fuse endoscopy system is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. Standard, forward-viewing endoscopy systems have just one camera so clinicians are switching to the Fuse system in an effort to improve the quality of their procedures.
"This will be a very important addition to our efforts to stop colorectal cancer in Israel," said Professor Ian M. Gralnek, MD, MSHS, FASGE, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology and Department of Gastroenterology, Rambam Health Care Campus, Haifa. Israel. "The study we completed here in Israel earlier this year showed we could find 71% more adenomas in patients with Fuse than we could with standard, forwarding viewing colonoscopes, these are very impressive results."
The news from the Ministry of Health enables EndoChoice to begin delivering Fuse endoscopy systems to their gastroenterology specialists' customers throughout Israel. Screening for early detection and prevention of colorectal cancer saves lives. Cancer of the colon has the highest incidence in Israel among all cancers (second only to breast cancer). Each year 3,200 people are diagnosed with colon cancer and more than 1,800 die. This means that every day on average - nine individuals are diagnosed and five die of colon cancer. 1
"This news is especially gratifying for our company because Fuse was invented by our R&D teams located in Caesarea," said Mark Gilreath, Founder and CEO at EndoChoice. "We have made significant commitments to Israel as one of few multinational medical device companies who have direct and broad presence in Israel; including R&D, manufacturing and sales. EndoChoice sees Israel as an important market also due to its high level of medicine, technology, education and entrepreneurship."
1 – Source: www.cancer.org.il
Based in Atlanta, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com
EndoChoice and Fuse™ are trademarks of EndoChoice, Inc.
For more information, press only:
Cel: +972 (0)52 4886848
For more information on Fuse™